<DOC>
	<DOC>NCT00313183</DOC>
	<brief_summary>This study will be the first evaluation of Symlin in adolescent subjects with type 1 diabetes mellitus and is designed to evaluate the blood levels (pharmacokinetics), biochemical and physiological effects (pharmacodynamics), and safety and tolerability of Symlin in these subjects.</brief_summary>
	<brief_title>A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>Diagnosed with type 1 diabetes mellitus for at least 1 year prior to screening Be on a stable regimen requiring multiple daily injections of basal and mealtime insulin or continuous subcutaneous insulin infusion for at least 2 weeks prior to screening HbA1c between 6.0% and 10.0%, inclusive, at screening Body weight &gt;=50 kg at screening Currently being treated with the following medications: *Any oral antihyperglycemic agent; *Drugs that directly affect gastrointestinal motility Has been previously treated with Symlin/pramlintide (or has participated in a Symlin/pramlintide clinical study) Has received any investigational drug within 1 month of screening</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>pediatric</keyword>
	<keyword>pramlintide</keyword>
	<keyword>Symlin</keyword>
	<keyword>Amylin</keyword>
</DOC>